SHENZHEN IN VIVO BIOMEDICINE TECHNOLOGY LIMITED COMPANY
发明人:
Peng Li,Yunxin Lai,Simiao Lin,Yao Yao
申请号：
US15112619
公开号：
US10093717B2
申请日:
2015.08.07
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and/or Toll-like receptor 2 intracellular domain(s)； compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.
